| Year |
Citation |
Score |
| 2021 |
Lin TL, Rizzieri DA, Ryan DH, Schiller GJ, Kolitz JE, Uy GL, Hogge DE, Solomon SR, Wieduwilt MJ, Ryan RJ, Faderl S, Cortes JE, Lancet JE. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Advances. 5: 1719-1728. PMID 33724305 DOI: 10.1182/bloodadvances.2020003510 |
0.393 |
|
| 2020 |
England JT, Saini L, Hogge D, Forrest D, Narayanan S, Power M, Nevill T, Kuchenbauer F, Hudoba M, Szkotak A, Brandwein J, Sanford D. Day 14 Bone Marrow Evaluation During Acute Myeloid Leukemia Induction in a Real-world Canadian Cohort. Clinical Lymphoma, Myeloma & Leukemia. PMID 32201130 DOI: 10.1016/J.Clml.2020.02.012 |
0.413 |
|
| 2020 |
Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Bixby D, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Faderl S, et al. Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML. Journal of Clinical Oncology. 38: 7510-7510. DOI: 10.1200/Jco.2020.38.15_Suppl.7510 |
0.422 |
|
| 2020 |
Ryan DH, Newell LF, Ritchie EK, Strickland SA, Hogge DE, Solomon SR, Schiller GJ, Wieduwilt MJ, Ryan RJ, Faderl S, Cortes JE. Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis Biology of Blood and Marrow Transplantation. 26: S9-S10. DOI: 10.1016/J.Bbmt.2019.12.073 |
0.414 |
|
| 2019 |
Kolitz JE, Strickland SA, Cortes JE, Hogge D, Lancet JE, Goldberg SL, Villa KF, Ryan RJ, Chiarella M, Louie AC, Ritchie EK, Stuart RK. Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. Leukemia & Lymphoma. 1-10. PMID 31760835 DOI: 10.1080/10428194.2019.1688320 |
0.476 |
|
| 2019 |
Kodad SG, Sutherland H, Limvorapitak W, Abou Mourad Y, Barnett MJ, Forrest D, Gerrie A, Hogge DE, Nantel SH, Narayanan S, Nevill T, Power M, Sanford D, Toze C, White J, et al. Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center. Clinical Lymphoma, Myeloma & Leukemia. PMID 31678079 DOI: 10.1016/j.clml.2019.09.619 |
0.39 |
|
| 2019 |
Matza LS, Deger KA, Howell TA, Koetter K, Yeager AM, Hogge D, Fisher V, Louie AC, Chung KC. Health State Utilities Associated with Treatment Options for Acute Myeloid Leukemia (AML). Journal of Medical Economics. 1. PMID 30775943 DOI: 10.1080/13696998.2019.1584108 |
0.376 |
|
| 2019 |
Kolitz JE, Ryan DH, Newell LF, Strickland SA, Hogge DE, Solomon SR, Schiller GJ, Ryan RJ, Faderl S, Cortes JE. Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy Blood. 134: 3856-3856. DOI: 10.1182/Blood-2019-124553 |
0.364 |
|
| 2019 |
Alahwal H, Song K, Yu M, Lewis C, Kuchenbauer F, Nantel S, Roth N, Mourad YA, Barnett M, Forrest D, Gerrie A, Hogge D, Narayanan S, Nevill T, Power M, et al. Maintenance therapy with either Lenalidomide or Bortezomib equally improves PFS and OS in High Risk Myeloma initially treated with Autotransplant. Clinical Lymphoma Myeloma and Leukemia. 19: e42-e43. DOI: 10.1016/J.Clml.2019.09.064 |
0.316 |
|
| 2019 |
Lin TL, Ryan DH, Ritchie EK, Strickland SA, Hogge DE, Solomon SR, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan RJ, Faderl S, Cortes JE. Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission Blood. 134: 1316-1316. DOI: 10.1016/J.Bbmt.2019.12.605 |
0.354 |
|
| 2019 |
Lin TL, Cortes JE, Newell LF, Ritchie EK, Hogge DE, Solomon SR, Schiller GJ, Wieduwilt MJ, Ryan DH, Ryan RJ, Louie AC. The Impact of Hematopoietic Cell Transplantation (HCT) on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML (sAML) Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.408 |
0.406 |
|
| 2018 |
Limvorapitak W, Barnett MJ, Hogge DE, Forrest DL, Nevill TJ, Narayanan S, Power MM, Nantel SH, Broady R, Song KW, Toze CL, Mourad YA, Sutherland HJ, Gerrie AS, White J, et al. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis. Clinical Lymphoma, Myeloma & Leukemia. PMID 30100330 DOI: 10.1016/J.Clml.2018.07.290 |
0.455 |
|
| 2018 |
Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017776112. PMID 30024784 DOI: 10.1200/Jco.2017.77.6112 |
0.483 |
|
| 2018 |
Zhu KY, Song KW, Connors JM, Leitch H, Barnett MJ, Ramadan K, Slack GW, Abou Mourad Y, Forrest DL, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Power MM, Sanford DS, et al. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. British Journal of Haematology. PMID 29741758 DOI: 10.1111/Bjh.15262 |
0.427 |
|
| 2018 |
Alzahrani M, Power M, Abou Mourad Y, Barnett M, Broady R, Forrest D, Gerrie A, Hogge D, Nantel S, Sanford D, Song K, Sutherland H, Toze C, Nevill T, Narayanan S. Improving Revised International Prognostic Scoring System (IPSS-R) Pre-Allogeneic Stem Cell Transplant Does Not Translate Into Better Post-Transplant Outcomes for Patients with Myelodysplastic Syndromes: a Single Center Experience. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29474870 DOI: 10.1016/J.Bbmt.2018.02.007 |
0.392 |
|
| 2018 |
Lin TL, Medeiros BC, Uy GL, Newell LF, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, et al. Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML). Journal of Clinical Oncology. 36: 7040-7040. DOI: 10.1200/Jco.2018.36.15_Suppl.7040 |
0.351 |
|
| 2018 |
Lin TL, Cortes JE, Newell LF, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Ryan R, et al. The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML Blood. 132: 2706-2706. DOI: 10.1182/Blood-2018-99-112557 |
0.423 |
|
| 2018 |
Alahwal H, Sutherland HJ, Kodad SG, Nantel SH, Abou Mourad Y, Barnett MJ, Forrest DL, Gerrie AS, Hogge DE, Narayanan S, Nevill TJ, Power M, Sanford D, Toze CL, White J, et al. Characteristics of Patients (pts) Who Relapse and Die of Multiple Myeloma (MM) within One Year Post Frontline Autologous Stem Cell Transplant (ASCT) in the Novel Agent Era: An Ultra-High Risk Population Blood. 132: 3440-3440. DOI: 10.1182/Blood-2018-99-111533 |
0.424 |
|
| 2018 |
Stubbins RJ, Lee L, Abou Mourad Y, Barnett MJ, Broady R, Forrest DL, Gerrie AS, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Power M, Song K, Sutherland HJ, Toze CL, et al. Older Adults with Acute Myeloid Leukemia in Rural Areas Are Less Likely to Receive Azacitidine with Worsened Overall Survival Blood. 132: 3989-3989. DOI: 10.1182/Blood-2018-99-111532 |
0.424 |
|
| 2018 |
Ryan DH, Uy GL, Cortes JE, Newell LF, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan R, et al. Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study Blood. 132: 1425-1425. DOI: 10.1182/Blood-2018-99-111514 |
0.389 |
|
| 2018 |
Lee L, Bruyere H, Barnett MJ, Broady R, Forrest DL, Gerrie AS, Hogge DE, Nantel SH, Narayanan S, Power M, Sanford D, Song K, Sutherland HJ, Toze CL, White J, et al. Unsuccessful Cytogenetics and Outcomes in Acute Leukemia Blood. 132: 2673-2673. DOI: 10.1182/Blood-2018-99-110470 |
0.397 |
|
| 2018 |
Kolitz J, Strickland SA, Cortes JE, Hogge D, Lancet JE, Goldberg S, Ryan RJ, Chiarella M, Louie AC, Uy GL. Outcomes in Older Patients with Newly Diagnosed, High-risk/Secondary Acute Myeloid Leukemia (sAML) Who Received Consolidation in a Phase 3 Study of CPX-351 versus Conventional 7+3/5+2 Cytarabine and Daunorubicin Clinical Lymphoma Myeloma and Leukemia. 18: S208-S209. DOI: 10.1016/J.Clml.2018.07.064 |
0.398 |
|
| 2017 |
Medeiros B, Hogge D, Newell L, Bixby D, Solomon S, Strickland S, Lin T, Erba H, Powell B, Podoltsev N, Ryan R, Chiarella M, Louie A, Lancet J. Overall Survival (OS) and Stem Cell Transplant (SCT) in Patients with FLT3 Mutations Treated with CPX-351 versus 7+3: Subgroup Analysis of a Phase 3 Study of Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML) Clinical Lymphoma Myeloma and Leukemia. 17: S286. DOI: 10.1200/Jco.2017.35.15_Suppl.E18507 |
0.489 |
|
| 2017 |
Kolitz JE, Strickland SA, Cortes JE, Hogge D, Lancet JE, Goldberg SL, Chung KC, Ryan R, Chiarella M, Louie AC, Stuart RK, Medeiros BC. Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML). Journal of Clinical Oncology. 35: 7036-7036. DOI: 10.1200/Jco.2017.35.15_Suppl.7036 |
0.398 |
|
| 2017 |
Sawler D, Sanford D, Brandwein JM, Sandhu I, Hogge D, Saini L. Two Cycles of Consolidation Chemotherapy Are Associated with Similar Clinical Outcomes to Three Cycles in AML Patients with Favorable Risk Cytogenetics Blood. 130: 464-464. DOI: 10.1182/Blood.V130.Suppl_1.464.464 |
0.472 |
|
| 2017 |
Lancet JE, Ritchie EK, Uy GL, Medeiros BC, Newell LF, Lin TL, Hogge D, Stuart RK, Strickland SA, Solomon SR, Stone RM, Kolitz JE, Bixby DL, Schiller GJ, Wieduwilt MJ, et al. Efficacy and Safety of CPX-351 Versus 7+3 in Older Adults with Secondary Acute Myeloid Leukemia: Combined Subgroup Analysis of Phase 2 and Phase 3 Studies Blood. 130: 2657-2657. DOI: 10.1182/Blood.V130.Suppl_1.2657.2657 |
0.372 |
|
| 2017 |
Medeiros BC, Lancet JE, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, et al. Rates of Adverse Events per Patient-Year in a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes Blood. 130: 1366-1366. DOI: 10.1182/Blood.V130.Suppl_1.1366.1366 |
0.38 |
|
| 2017 |
Matza L, Deger K, Howell T, Hillgruber N, Yeager A, Hogge D, Fisher V, Louie A, Chung K. Health State Utilities Associated with Treatment Options for Acute Myeloid Leukemia (AML) Value in Health. 20: A448. DOI: 10.1016/J.Jval.2017.08.283 |
0.312 |
|
| 2017 |
Kolitz J, Strickland S, Cortes J, Hogge D, Lancet J, Goldberg S, Chung K, Ryan R, Chiarella M, Louie A, Stuart R, Medeiros B. Overall Survival (OS) by Outpatient versus Inpatient Consolidation in a Phase 3 Study of CPX-351 versus 7+3 in Older Adults with Newly Diagnosed, High-Risk Acute Myeloid Leukemia (AML) Clinical Lymphoma Myeloma and Leukemia. 17: S287. DOI: 10.1016/J.Clml.2017.07.073 |
0.38 |
|
| 2017 |
Lancet J, Uy GL, Cortes J, Newell LF, Lin TL, Ritchie E, Stuart R, Strickland S, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, et al. Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 with Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial Biology of Blood and Marrow Transplantation. 23: S38-S39. DOI: 10.1016/J.Bbmt.2016.12.090 |
0.4 |
|
| 2016 |
Kliman D, Barnett M, Broady R, Forrest D, Gerrie A, Hogge D, Nantel S, Narayanan S, Nevill T, Power M, Sanford D, Song K, Sutherland H, Toze C, Abou Mourad Y. Comparison of a pediatric-inspired treatment protocol versusstandard-intensity chemotherapy for young adults with standard-riskBCR-ABL negative acute lymphoblastic leukemia. Leukemia & Lymphoma. 1-7. PMID 27561638 DOI: 10.1080/10428194.2016.1222376 |
0.436 |
|
| 2016 |
Khamenehfar A, Gandhi MK, Chen Y, Hogge DE, Li PC. Dielectrophoretic Microfluidic Chip Enables Single-Cell Measurements for Multidrug Resistance in Heterogeneous Acute Myeloid Leukemia Patient Samples. Analytical Chemistry. PMID 27149245 DOI: 10.1021/Acs.Analchem.5B04446 |
0.319 |
|
| 2016 |
Cressman S, Karsan A, Hogge DE, McPherson E, Bolbocean C, Regier DA, Peacock SJ. Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia. British Journal of Haematology. PMID 27098559 DOI: 10.1111/Bjh.14076 |
0.32 |
|
| 2016 |
Michelis FV, Atenafu EG, Couban S, Frazer J, Shivakumar S, Hogge DE, Toze CL, Rajkhan W, Kim HJ, Daly A, Slaby J, Finke J, Kiss T, Bredeson C, Sabloff M, et al. Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study. Bone Marrow Transplantation. PMID 26974273 DOI: 10.1038/Bmt.2016.60 |
0.42 |
|
| 2016 |
Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, et al. Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. Journal of Clinical Oncology. 34: 7000-7000. DOI: 10.1200/Jco.2016.34.15_Suppl.7000 |
0.436 |
|
| 2016 |
Lancet JE, Hoering A, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, et al. Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial Blood. 128: 906-906. DOI: 10.1182/Blood.V128.22.906.906 |
0.416 |
|
| 2016 |
Medeiros BC, Lancet JE, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, et al. Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial Blood. 128: 902-902. DOI: 10.1182/Blood.V128.22.902.902 |
0.366 |
|
| 2016 |
Alzahrani M, Savage KJ, Toze CL, Sehn LH, Broady R, Abou Mourad Y, Barnett MJ, Forrest DL, Gerrie AS, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Power MM, Sanford D, et al. Outcome of Patients with Peripheral T-Cell Lymphoma Undergoing Allogeneic Stem Cell in British Columbia Blood. 128: 5852-5852. DOI: 10.1182/Blood.V128.22.5852.5852 |
0.469 |
|
| 2016 |
Alzahrani M, Power MM, Nevill E, Abou Mourad Y, Barnett MJ, Broady R, Forrest DL, Gerrie AS, Hogge DE, Nantel SH, Sanford D, Sutherland HJ, Toze CL, Song KW, Song KW, et al. Improving Revised International Prognostic Scoring System (IPSS-R) Pre-Allogeneic Stem Cell Transplant Does Not Translate into Better Post-Transplant Outcomes for Patients with Myelodysplastic Syndromes Blood. 128: 4662-4662. DOI: 10.1182/Blood.V128.22.4662.4662 |
0.438 |
|
| 2016 |
Siddiqui A, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Broady R, Forrest DL, Narayanan S, Power MM, Song KW, Toze CL, Abou Mourad Y, Sutherland HJ, Gerrie AS, Sanford D. Long-Term Outcomes of Patients with Acute Myeloid Leukemia Treated with Salvage High-Dose Etoposide and Cyclophosphamide Blood. 128: 2814-2814. DOI: 10.1182/Blood.V128.22.2814.2814 |
0.475 |
|
| 2016 |
Zhu KY, Song KW, Connors JM, Tucker T, Slack GW, Abou Mourad Y, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Power MM, Sanford D, Toze CL, et al. Population-Based Survival Outcomes in Adult Patients with Burkitt Lymphoma (BL) Treated with Cyclophosphamide, Vincristine, Doxorubicin, High-Dose Methotrexate (CODOX-M)/Ifosfamide, Etoposide and High-Dose Cytarabine (IVAC) Plus or Minus Rituximab (R) in British Columbia (BC), Canada Blood. 128: 1113-1113. DOI: 10.1182/Blood.V128.22.1113.1113 |
0.409 |
|
| 2016 |
Cortes J, Gammon G, Khaled S, Martinelli G, Kramer A, Steffen B, Hogge D, Jonas B, Dombret H, Perl A. Phase 3 study of quizartinib (AC220) monotherapy vs salvage chemotherapy (SC) in patients (pts) with FLT3-ITD+ acute myeloid leukemia (AML) refractory to or relapsed (R/R) after 1st-line treatment with or without hematopoietic stem cell transplant (HSCT) consolidation: the QuANTUM-R study Annals of Oncology. 27: vi327. DOI: 10.1093/Annonc/Mdw375.43 |
0.392 |
|
| 2015 |
Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, ... ... Hogge D, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. The Lancet. Oncology. PMID 26234174 DOI: 10.1016/S1470-2045(15)00201-6 |
0.319 |
|
| 2015 |
Yuan X, Koehn J, Hogge DE. Identification of prognostic subgroups among acute myeloid leukemia patients with intermediate risk cytogenetics using a flow-cytometry-based assessment of ABC-transporter function. Leukemia Research. 39: 689-95. PMID 26002514 DOI: 10.1016/J.Leukres.2015.04.018 |
0.322 |
|
| 2015 |
Nair AP, Barnett MJ, Broady RC, Hogge DE, Song KW, Toze CL, Nantel SH, Power MM, Sutherland HJ, Nevill TJ, Abou Mourad Y, Narayanan S, Gerrie AS, Forrest DL. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 1437-44. PMID 25865648 DOI: 10.1016/J.Bbmt.2015.04.005 |
0.486 |
|
| 2015 |
Sun H, Savage KJ, Karsan A, Slack GW, Gascoyne RD, Toze CL, Sehn LH, Abou Mourad Y, Barnett MJ, Broady RC, Connors JM, Forrest DL, Gerrie AS, Hogge DE, Narayanan S, et al. Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma & Leukemia. 15: 341-8. PMID 25656914 DOI: 10.1016/J.Clml.2014.12.015 |
0.439 |
|
| 2015 |
Cortes JE, Goldberg SL, Feldman EJ, Rizzeri DA, Hogge DE, Larson M, Pigneux A, Recher C, Schiller G, Warzocha K, Kantarjian H, Louie AC, Kolitz JE. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 121: 234-42. PMID 25223583 DOI: 10.1002/Cncr.28974 |
0.472 |
|
| 2015 |
Kliman DS, Barnett MJ, Broady R, Forrest DL, Gerrie AS, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Power MM, Song K, Sutherland HJ, Toze CL, Abou Mourad Y. Pediatric-Based Versus Adult Treatment Protocols in Young Adults (18-40 years) with Standard Risk Acute Lymphoblastic Leukemia: The BC Cancer Agency Experience Blood. 126: 3770-3770. DOI: 10.1182/Blood.V126.23.3770.3770 |
0.478 |
|
| 2014 |
Brandwein JM, Kassis J, Leber B, Hogge D, Howson-Jan K, Minden MD, Galarneau A, Pouliot JF. Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression. British Journal of Haematology. 167: 664-70. PMID 25160658 DOI: 10.1111/bjh.13094 |
0.309 |
|
| 2014 |
Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 123: 3239-46. PMID 24687088 DOI: 10.1182/Blood-2013-12-540971 |
0.46 |
|
| 2014 |
Minden MD, Hogge DE, Weir SJ, Kasper J, Webster DA, Patton L, Jitkova Y, Hurren R, Gronda M, Goard CA, Rajewski LG, Haslam JL, Heppert KE, Schorno K, Chang H, et al. Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. American Journal of Hematology. 89: 363-8. PMID 24273151 DOI: 10.1002/Ajh.23640 |
0.384 |
|
| 2014 |
Cressman S, Karsan A, Hogge DE, McPherson E, Peacock S. The Cost-Effectiveness of Clinical Genomic Tests to Aid CR1 Treatment Decisions in Intermediate-Risk AML Blood. 124: 2650-2650. DOI: 10.1182/Blood.V124.21.2650.2650 |
0.358 |
|
| 2014 |
Swic SJ, MacPhail AGT, Dalal CB, Huang SJ, Gerrie AS, Nevill TJ, Sutherland HJ, Broady R, Nantel SH, Narayanan S, Song K, Abou Mourad YR, Hogge DE, Power MM, Barnett MJ, et al. Prognostic Factors and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Vs. Non-Transplant Chronic Lymphocytic Leukemia (CLL) Patients: A Comparative Analysis with the Leukemia/BMT Program of British Columbia (BC) and the BC Provincial CLL Database Blood. 124: 2549-2549. DOI: 10.1182/Blood.V124.21.2549.2549 |
0.453 |
|
| 2014 |
Nair A, Barnett MJ, Hogge DE, Song K, Toze CL, Nantel SH, Power MM, Narayanan S, Broady R, Sutherland HJ, Nevill TJ, Abou Mourad YR, Gerrie AS, Forrest DL. Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Failing Treatment with Tyrosine Kinase Inhibitors Blood. 124: 1250-1250. DOI: 10.1182/Blood.V124.21.1250.1250 |
0.453 |
|
| 2013 |
Lubieniecka JM, Graham J, Heffner D, Mottus R, Reid R, Hogge D, Grigliatti TA, Riggs WK. A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor. Frontiers in Genetics. 4: 231. PMID 24273552 DOI: 10.3389/Fgene.2013.00231 |
0.346 |
|
| 2013 |
Xing Y, Hogge DE. Combined inhibition of the phosphoinosityl-3-kinase (PI3Kinase) P110δ subunit and mitogen-extracellular activated protein kinase (MEKinase) shows synergistic cytotoxicity against human acute myeloid leukemia progenitors. Leukemia Research. 37: 697-704. PMID 23522913 DOI: 10.1016/J.Leukres.2013.03.003 |
0.396 |
|
| 2013 |
Rosen DB, Harrington KH, Cordeiro JA, Leung LY, Putta S, Lacayo N, Laszlo GS, Gudgeon CJ, Hogge DE, Hawtin RE, Cesano A, Walter RB. AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. Plos One. 8: e53518. PMID 23320091 DOI: 10.1371/Journal.Pone.0053518 |
0.36 |
|
| 2013 |
Feldman EJ, Lancet JE, Kolitz JE, Hogge D, Tallman MS, Goldberg SL, Kovacsovics T, Louie AC, Cortes JE. Multivariate analysis of factors affecting overall survival, event free survival, and 60-day mortality among AML patients treated with CPX-351 or intensive chemotherapy. Journal of Clinical Oncology. 31: 7100-7100. DOI: 10.1200/Jco.2013.31.15_Suppl.7100 |
0.454 |
|
| 2013 |
Frankel AE, Konopleva M, Hogge D, Rizzieri D, Brooks C, Cirrito T, Kornblau SM, Borthakur G, Bivins C, Garcia-Manero G, Ravandi F, Kadia TM, Andreeff M, Cortes JE, Hoberman K, et al. Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. Journal of Clinical Oncology. 31: 7029-7029. DOI: 10.1200/Jco.2013.31.15_Suppl.7029 |
0.457 |
|
| 2013 |
Kalashetty M, Dalal BI, Roland KJ, Mourad YA, Barnett MJ, Broady R, Forrest DL, Hogge DE, Gerrie AS, Nantel SH, Power M, Song KW, Sutherland HJ, Toze CL, Nevill TJ, et al. Improved Survival In Adults With Mixed-Phenotype Acute Leukemia Following Stem Cell Transplantation (SCT): A Single Centre Experience Blood. 122: 5540-5540. DOI: 10.1182/Blood.V122.21.5540.5540 |
0.432 |
|
| 2013 |
Frankel AE, Woo JH, Mauldin JP, Carraway HE, Frankfurt O, Forman SJ, Vasu S, Pemmaraju N, Konopleva M, Hogge DE, Garanache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Bergstein I, et al. An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Blood. 122: 2682-2682. DOI: 10.1182/Blood.V122.21.2682.2682 |
0.481 |
|
| 2013 |
Sun H(, Savage KJ, Karsan A, Slack GW, Toze CL, Sehn LH, Abou Mourad YR, Barnett MJ, Broady R, Connors JM, Forrest D, Gascoyne RD, Gerrie AS, Hogge DE, Narayanan S, et al. Outcome Of Patients With Double-Hit Lymphomas Treated With CODOX-M/IVAC + R Followed By Hematopoietic Stem Cell Transplantation In British Columbia Blood. 122: 1788-1788. DOI: 10.1182/Blood.V122.21.1788.1788 |
0.456 |
|
| 2012 |
Xing Y, Gerhard B, Hogge DE. Selective small molecule inhibitors of p110α and δ isoforms of phosphoinosityl-3-kinase are cytotoxic to human acute myeloid leukemia progenitors. Experimental Hematology. 40: 922-33. PMID 22828407 DOI: 10.1016/J.Exphem.2012.07.006 |
0.407 |
|
| 2012 |
Toze CL, Dalal CB, Nevill TJ, Gillan TL, Abou Mourad YR, Barnett MJ, Broady RC, Forrest DL, Hogge DE, Nantel SH, Power MM, Song KW, Sutherland HJ, Smith CA, Narayanan S, et al. Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort. British Journal of Haematology. 158: 174-85. PMID 22640008 DOI: 10.1111/J.1365-2141.2012.09170.X |
0.466 |
|
| 2012 |
Rosen DB, Cordeiro JA, Cohen A, Lacayo N, Hogge D, Hawtin RE, Cesano A. Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML. Leukemia Research. 36: 900-4. PMID 22521550 DOI: 10.1016/J.Leukres.2012.02.022 |
0.322 |
|
| 2012 |
Kim HP, Bernard L, Berkowitz J, Nitta J, Hogge DE. Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia. Cytometry. Part B, Clinical Cytometry. 82: 283-94. PMID 22508650 DOI: 10.1002/Cyto.B.21028 |
0.368 |
|
| 2012 |
Dalal BI, Mansoor S, Manna M, Pi S, Di Sauro G, Hogge DE. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia Clinical Lymphoma, Myeloma and Leukemia. 12: 274-279. PMID 22481022 DOI: 10.1016/J.Clml.2012.01.003 |
0.323 |
|
| 2012 |
Cheung AM, Leung D, Rostamirad S, Dhillon K, Miller PH, Droumeva R, Brinkman RR, Hogge D, Roy DC, Eaves CJ. Distinct but phenotypically heterogeneous human cell populations produce rapid recovery of platelets and neutrophils after transplantation. Blood. 119: 3431-9. PMID 22374695 DOI: 10.1182/Blood-2011-12-398024 |
0.412 |
|
| 2012 |
Tantiworawit A, Power MM, Barnett MJ, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Abou-Mourad YR, Narayanan S, Broady RC, Forrest DL. Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy. Leukemia & Lymphoma. 53: 1321-6. PMID 22192245 DOI: 10.3109/10428194.2011.652108 |
0.459 |
|
| 2012 |
Lancet JE, Cortes JE, Kovacsovics T, Hogge D, Kolitz JE, Tallman MS, Chiarella M, Louie AC, Feldman EJ. A comparison of CR versus CRi response following CPX-351 treatment of newly diagnosed AML in elderly patients (pts). Journal of Clinical Oncology. 30: 6601-6601. DOI: 10.1200/Jco.2012.30.15_Suppl.6601 |
0.375 |
|
| 2012 |
Dalal CB, Shanmukhaiah C, Nevill TJ, Barnett MJ, Nantel SH, Hogge DE, Forrest DL, Sutherland HJ, Song KW, Broady R, Power MM, Narayanan S, Mourad YRA, Shepherd JD, Young SS, et al. Factors Predictive for Graft Failure Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia in a Population-Based Provincial Transplant Cohort Blood. 120: 4132-4132. DOI: 10.1182/Blood.V120.21.4132.4132 |
0.371 |
|
| 2012 |
Lancet JE, Cortes JE, Kovacsovics T, Hogge DE, Kolitz JE, Tallman MS, Hoering A, Chiarella MT, Louie AC, Feldman E. CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors Blood. 120: 3626-3626. DOI: 10.1182/Blood.V120.21.3626.3626 |
0.466 |
|
| 2012 |
Konopleva M, Hogge DE, Rizzieri DA, Cirrito TP, Kornblau SM, Borthakur G, Bivins C, Garcia-Manero G, Kadia TM, Ravandi F, Andreeff M, Cortes JE, Hoberman K, Szarek M, Rowinsky E, et al. SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML Blood. 120: 3625-3625. DOI: 10.1182/Blood.V120.21.3625.3625 |
0.466 |
|
| 2012 |
Minden MD, Hogge DE, Weir S, Kasper J, Patton L, Jitkova Y, Gronda M, Hurren R, Rajewski L, Schorno K, Chang H, Brandwein JM, Gupta V, Schuh AC, Trudel S, et al. Clinical Proof of Concept Trial of Oral Ciclopirox Olamine in Patients with Relapsed/Refractory Hematologic Malignancy Blood. 120: 1372-1372. DOI: 10.1182/Blood.V120.21.1372.1372 |
0.414 |
|
| 2011 |
Kim HP, Gerhard B, Harasym TO, Mayer LD, Hogge DE. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Experimental Hematology. 39: 741-50. PMID 21530609 DOI: 10.1016/j.exphem.2011.04.001 |
0.341 |
|
| 2011 |
Venner CP, Connors JM, Sutherland HJ, Shepherd JD, Hamata L, Mourad YA, Barnett MJ, Broady R, Forrest DL, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Nitta J, Power MM, et al. Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months). Leukemia & Lymphoma. 52: 34-41. PMID 21133716 DOI: 10.3109/10428194.2010.531409 |
0.434 |
|
| 2011 |
Seftel MD, Paulson K, Doocey R, Song K, Czaykowski P, Coppin C, Forrest D, Hogge D, Kollmansberger C, Smith CA, Shepherd JD, Toze CL, Murray N, Sutherland H, Nantel S, et al. Long-term follow-up of patients undergoing auto-SCT for advanced germ cell tumour: a multicentre cohort study. Bone Marrow Transplantation. 46: 852-7. PMID 21042312 DOI: 10.1038/Bmt.2010.250 |
0.444 |
|
| 2011 |
Kanda J, Rizzieri DA, Gasparetto C, Long GD, Chute JP, Sullivan KM, Morris A, Smith CA, Hogge DE, Nitta J, Song K, Niedzwiecki D, Chao NJ, Horwitz ME. Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 17: 867-74. PMID 20868761 DOI: 10.1016/j.bbmt.2010.09.009 |
0.445 |
|
| 2011 |
Toze CL, Dalal CB, Nevill TJ, Barnett MJ, Nantel SH, Forrest DL, Hogge DE, Sutherland HJ, Song KW, Mourad YA, Broady R, Power MM, Narayanan S, Gillan TL, Smith CA, et al. Outcomes for Patients Aged 60 and Over Are Similar to Younger Patients Following Reduced-Intensity Allogeneic Stem Cell Transplant for CLL Blood. 118: 3100-3100. DOI: 10.1182/Blood.V118.21.3100.3100 |
0.395 |
|
| 2011 |
Krishnan S, Li H, Mourad YRA, Barnett MJ, Broady R, Forrest DL, Nantel SH, Narayanan S, Nevill TJ, Power MM, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Hogge DE. Elderly AML Patients Treated with Intensive Chemotherapy- Developing A Prognostic Scoring System. A Study On 381 Patients From British Columbia Blood. 118: 2561-2561. DOI: 10.1182/Blood.V118.21.2561.2561 |
0.463 |
|
| 2011 |
Tantiworawit A, Abou Mourad Y, Barnett MJ, Broady R, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Power MM, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Forrest DL. Clonal Evolution but Not Variant Chromosomal Translocations Is An Adverse Prognostic Marker for Cytogenetic Response and Survival in CML Patients Treated with Imatinib Blood. 118: 1694-1694. DOI: 10.1182/Blood.V118.21.1694.1694 |
0.423 |
|
| 2011 |
Xing Y, Gerhard B, Hogge DE. Selective Small Molecule Inhibition of P110α and δ Isoforms of PI3 Kinase Is Cytotoxic to Human AML Progenitors Blood. 118: 1556-1556. DOI: 10.1182/Blood.V118.21.1556.1556 |
0.355 |
|
| 2011 |
Rosen DB, Cordeiro J, Cohen AC, Lacayo N, Hogge D, Cesano A, Hawtin RE. Abstract B72: Assessing specific biological mechanisms of drug resistance in adult and pediatric AML. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B72 |
0.316 |
|
| 2010 |
Bastien JP, Krosl G, Therien C, Rashkovan M, Scotto C, Cohen S, Allan DS, Hogge D, Egeler RM, Perreault C, Roy DC. Photodepletion differentially affects CD4+ Tregs versus CD4+ effector T cells from patients with chronic graft-versus-host disease. Blood. 116: 4859-69. PMID 20798236 DOI: 10.1182/Blood-2010-03-273193 |
0.36 |
|
| 2010 |
Muranyi AL, Dedhar S, Hogge DE. Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. Leukemia Research. 34: 1358-65. PMID 20193963 DOI: 10.1016/J.Leukres.2010.01.006 |
0.402 |
|
| 2010 |
Kim HP, Frankel AE, Hogge DE. A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia Leukemia Research. 34: 1035-1042. PMID 20137810 DOI: 10.1016/J.Leukres.2009.12.008 |
0.306 |
|
| 2010 |
Wright MP, Shepherd JD, Barnett MJ, Nantel SH, Sutherland HJ, Toze CL, Hogge DE, Nevill TJ, Song KW, Abou Mourad YR, Narayanan S, Power MM, Smith CA, Forrest DL. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 16: 639-46. PMID 20005967 DOI: 10.1016/J.Bbmt.2009.11.026 |
0.465 |
|
| 2010 |
Abou-Mourad YR, Lau BC, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Lavoie JC. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplantation. 45: 295-302. PMID 19597425 DOI: 10.1038/Bmt.2009.128 |
0.404 |
|
| 2010 |
Lancet J, Feldman E, Kolitz J, Tallman M, Hogge DE, Louie A. Phase IIB Randomized Study of CPX-351 Versus Conventional Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: An Interim Analysis Clinical Lymphoma Myeloma and Leukemia. 10: E28. DOI: 10.3816/Clml.2010.N.038 |
0.468 |
|
| 2010 |
Lancet JE, Cortes JE, Hogge DE, Tallman M, Kovacsovics T, Damon LE, Ritchie E, Komrokji RS, Louie AC, Feldman EJ. Phase 2B Randomized Study of CPX-351 Vs. Cytarabine (CYT) + Daunorubicin (DNR) (7+3 Regimen) In Newly Diagnosed AML Patients Aged 60–75 Blood. 116: 655-655. DOI: 10.1182/Blood.V116.21.655.655 |
0.44 |
|
| 2010 |
Venner CP, Sutherland H, Shepherd J, Mourad YA, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Nitta J, Power M, Toze C, Smith C, Song K. The Use of Novel Agents In Patients with Multiple Myeloma Initially Treated with Allogeneic Stem Cell Transplantation Results In A Significant Prolongation of Post Relapse Survival. Blood. 116: 4580-4580. DOI: 10.1182/Blood.V116.21.4580.4580 |
0.421 |
|
| 2010 |
Bastien J, Krosl G, Therien C, Rashkovan M, Scotto C, Cohen S, Allan DS, Hogge DE, Egeler RM, Perreault C, Roy D. Novel Photodepletion Strategy to Preserve and Expand Tregs While Eliminating CD4+ Effector T Cells From Patients with Chronic Graft-Versus-Host Disease Blood. 116: 353-353. DOI: 10.1182/Blood.V116.21.353.353 |
0.369 |
|
| 2010 |
Toze C, Dalal CB, Gillan TL, Nevill TJ, Barnett MJ, Nantel SH, Hogge DE, Forrest DL, Sutherland H, Song K, Broady R, Power M, Narayanan S, Smith CA, Shepherd J. Allogeneic Hematopoietic Stem Cell Transplantation for CLL: Eradication of Specific FISH Abnormalities with Relation to Gvhd and Transplant Outcomes. Blood. 116: 3465-3465. DOI: 10.1182/Blood.V116.21.3465.3465 |
0.41 |
|
| 2010 |
Konopleva M, Hogge DE, Rizzieri DA, Cirrito TP, Liu JS, Kornblau SM, Grable M, Hwang I, Borthakur G, Mankin A, Bivins C, Garcia-Manero G, Kadia T, Harris D, Ravandi F, et al. Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS Blood. 116: 3298-3298. DOI: 10.1182/Blood.V116.21.3298.3298 |
0.506 |
|
| 2010 |
Noparast M, Hogge D, Spinelli JJ, Gotay C, Bajdik C. Abstract B77: Ethnicity and hematopoietic stem cell transplantation (HSCT) outcomes in British Columbia, Canada Cancer Epidemiology, Biomarkers & Prevention. 19. DOI: 10.1158/1055-9965.Disp-10-B77 |
0.411 |
|
| 2010 |
Tantiworawit A, Barnett M, Forrest D, Hogge D, Nantel S, Narayanan S, Nevill T, Power M, Shepherd J, Smith C, Song K, Sutherland H, Toze C, Abou Mourad Y. Outcome Of Elderly Patients With Acute Lymphoblastic Leukemia (EALL) With Chemotherapy: The Vancouver Experience Biology of Blood and Marrow Transplantation. 16: S233. DOI: 10.1016/J.Bbmt.2009.12.239 |
0.4 |
|
| 2009 |
Nevill TJ, Shepherd JD, Sutherland HJ, Abou Mourad YR, Lavoie JC, Barnett MJ, Nantel SH, Toze CL, Hogge DE, Forrest DL, Song KW, Power MM, Nitta JY, Dai Y, Smith CA. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 15: 205-13. PMID 19167680 DOI: 10.1016/J.Bbmt.2008.11.015 |
0.447 |
|
| 2009 |
Calado RT, Regal JA, Hills M, Yewdell WT, Dalmazzo LF, Zago MA, Lansdorp PM, Hogge D, Chanock SJ, Estey EH, Falcão RP, Young NS. Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 106: 1187-92. PMID 19147845 DOI: 10.1073/Pnas.0807057106 |
0.384 |
|
| 2009 |
Forrest DL, Trainor S, Brinkman RR, Barnett MJ, Hogge DE, Nevill TJ, Shepherd JD, Nantel SH, Toze CL, Sutherland HJ, Song KW, Lavoie JC, Power MM, Abou-Mourad Y, Smith CA. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leukemia Research. 33: 271-5. PMID 18762338 DOI: 10.1016/J.Leukres.2008.07.015 |
0.334 |
|
| 2009 |
Song K, Sutherland HJ, Shepherd JD, Abou Mourad Y, Barnett MJ, Forrest DL, Hogge DE, Narayanan S, Nantel SH, Power MM, Toze CL, Smith C, Nevill TJ. Short Progression Free Survival Post Non-Myeloablative Sibling Allogeneic Stem Cell Transplantion for Multiple Myeloma. Blood. 114: 4323-4323. DOI: 10.1182/Blood.V114.22.4323.4323 |
0.486 |
|
| 2009 |
Venner CP, Connors JM, Sutherland HJ, Shepherd JD, Hamata L, Mourad YA, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Narayanan S, Nevill TJ, Nitta J, Power MM, Toze CL, et al. Exposure to Novel Agents Increases Post Relapse Survival in Patients with High Risk Myeloma Defined by Early Relapse (<12 months). Blood. 114: 2872-2872. DOI: 10.1182/Blood.V114.22.2872.2872 |
0.469 |
|
| 2009 |
Rosen DB, Cordeiro JA, Soper DM, Huang Y, Hogge DE, Walter RB, Cesano A, Fantl WJ. Distinct Signaling Profiles of Gemtuzumab Ozogamicin Responsiveness and Refractoriness in Acute Myeloid Leukemia. Blood. 114: 2745-2745. DOI: 10.1182/Blood.V114.22.2745.2745 |
0.345 |
|
| 2009 |
Kim P, Gerhard G, Harasym TO, Lim W, Zisman N, Mayer LD, Hogge DE. Improved Selectivity against Acute Myeloid Leukemia (AML) Blasts Over Normal Hematopoietic Progenitors for Cytarabine: Daunorubicin Delivered as CPX-351 Liposome Injection. Blood. 114: 2071-2071. DOI: 10.1182/Blood.V114.22.2071.2071 |
0.442 |
|
| 2009 |
Ma W, Warkentin D, Yeung J, Shepherd JD, Mourad YA, Smith C, Song K, Hogge DE, Barnett MJ, Nevill TJ, Nantel SH, Toze CL, Sutherland HJ, Forrest DL, Narayanan S, et al. High Incidence of Invasive Fungal Infections in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation. Blood. 114: 1136-1136. DOI: 10.1182/Blood.V114.22.1136.1136 |
0.464 |
|
| 2009 |
Lancet JE, Feldman EJ, Kolitz JE, Tallman MS, Hogge DE, Komrokji RS, Chiarella MT, Louie AC. Phase IIb Randomized Study of CPX-351 Vs. Conventional Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: Safety Report. Blood. 114: 1033-1033. DOI: 10.1182/Blood.V114.22.1033.1033 |
0.427 |
|
| 2008 |
Ramadan KM, Connors JM, Al-Tourah AJ, Song KW, Gascoyne RD, Barnett MJ, Nevill TJ, Shepherd JD, Nantel SH, Sutherland HJ, Forrest DL, Hogge DE, Lavoie JC, Abou-Mourad YR, Chhanabhai M, et al. Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplantation. 42: 601-8. PMID 18695664 DOI: 10.1038/Bmt.2008.220 |
0.412 |
|
| 2008 |
Nevill TJ, Hogge DE, Toze CL, Nantel SH, Power MM, Abou Mourad YR, Song KW, Lavoie JC, Forrest DL, Barnett MJ, Shepherd JD, Nitta JY, Wong S, Sutherland HJ, Smith CA. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML. Bone Marrow Transplantation. 42: 659-66. PMID 18679372 DOI: 10.1038/Bmt.2008.226 |
0.379 |
|
| 2008 |
Frankel A, Liu JS, Rizzieri D, Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia Leukemia and Lymphoma. 49: 543-553. PMID 18297533 DOI: 10.1080/10428190701799035 |
0.392 |
|
| 2008 |
Ho MM, Hogge DE, Ling V. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Experimental Hematology. 36: 433-42. PMID 18249061 DOI: 10.1016/J.Exphem.2007.11.014 |
0.419 |
|
| 2008 |
Ramadan KM, Connors JM, Al-Tourah A, Gascoyne RD, Song KW, Barnett MJ, Nantel SH, Nevill TJ, Shepherd JD, Sutherland HJ, Lavoie J, Forrest DL, Hogge DE, Voss N, Brinkman R, et al. Salvage Therapy with Allogeneic Stem Cell Transplantation Results in Better Outcome for Patients with Relapsed/Refractory Follicular Lymphoma Compared to Those with Transformed Non-Hodgkin Lymphoma: A Population-Based Comparative Study. Blood. 112: 975-975. DOI: 10.1182/Blood.V112.11.975.975 |
0.355 |
|
| 2008 |
Muranyi AL, Dedhar S, Hogge DE. QLT0267, a Small Molecule Inhibitor of ILK and FLT3 Is Cytotoxic to Acute Myeloid Leukemia (AML) ‘Stem Cells’ Detected in Immunodeficient Mice. Blood. 112: 950-950. DOI: 10.1182/Blood.V112.11.950.950 |
0.364 |
|
| 2008 |
Ramadan KM, Connors JM, Al-Tourah A, Gascoyne RD, Song KW, Barnett MJ, Nantel SH, Nevill TJ, Shepherd JD, Sutherland HJ, Lavoie J, Forrest DL, Hogge DE, Voss N, Brinkman R, et al. Autologous Stem Cell Transplantation Is Superior to Myeloablative Allogeneic SCT as a Salvage Therapy for Patients with Refractory/Relapsed Transformed Lymphoma Blood. 112: 4459-4459. DOI: 10.1182/Blood.V112.11.4459.4459 |
0.458 |
|
| 2008 |
Toze CL, Sangara RN, Connors JM, Nevill TJ, Shepherd JD, Lavoie J, Barnett MJ, Nantel SH, Voss N, Hogge DE, Sutherland HJ, Forrest DL, Song KW, Mourad YA, Power MM, et al. Impact of Comorbidity Index on Outcome with Allogeneic Hematopoetic Stem Cell Transplantation for Chronic Lymphocytic Leukemia Blood. 112: 3305-3305. DOI: 10.1182/Blood.V112.11.3305.3305 |
0.469 |
|
| 2008 |
Ramadan KM, Song KW, Connors JM, Al-Tourah A, Gascoyne RD, Barnett MJ, Nantel SH, Nevill TJ, Shepherd JD, Sutherland HJ, Lavoie J, Forrest DL, Hogge DE, Voss N, Brinkman R, et al. Comparison of Outcome Between Refractory/Relapsed De Novo Diffuse Large B-Cell and Transformed Lymphoma Using Related and Unrelated Allogeneic Hematopoietic SCT. Blood. 112: 2173-2173. DOI: 10.1182/Blood.V112.11.2173.2173 |
0.444 |
|
| 2008 |
Narayanan S, Barnett M, Abou Mourad Y, Forrest D, Hogge D, Lavoie J, Nantel S, Shepherd J, Song K, Sutherland H, Toze C, Smith C, Power M, Nevill T. 298: Higher CD 34 Cell Doses Reduce Non Relapse Mortality (NRM) and do not Increase the Incidence of Graft Versus Host Disease (GVHD) following Unrelated Donor Blood Stem Cell Transplantation (SCT) Biology of Blood and Marrow Transplantation. 14: 110-111. DOI: 10.1182/Blood.V110.11.5091.5091 |
0.407 |
|
| 2007 |
Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 13: 925-31. PMID 17640596 DOI: 10.1016/J.Bbmt.2007.04.006 |
0.49 |
|
| 2007 |
Halim TY, Song KW, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Lavoie JC. Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septicemia. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 18: 1246-52. PMID 17442662 DOI: 10.1093/Annonc/Mdm112 |
0.418 |
|
| 2007 |
Song KW, Barnett MJ, Gascoyne RD, Chhanabhai M, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Voss NJ, Connors JM. Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 18: 535-40. PMID 17158775 DOI: 10.1093/Annonc/Mdl426 |
0.491 |
|
| 2007 |
Greenwood MJ, Seftel MD, Richardson C, Barbaric D, Barnett MJ, Bruyere H, Forrest DL, Horsman DE, Smith C, Song K, Sutherland HJ, Toze CL, Nevill TJ, Nantel SH, Hogge DE. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leukemia & Lymphoma. 47: 1245-52. PMID 16923553 DOI: 10.1080/10428190600572673 |
0.427 |
|
| 2007 |
Frankel AE, Weir MA, Hall PD, Holguin M, Cable C, Rizzieri DA, Hogge DE. Induction of remission in patients with acute myeloid leukemia without prolonged myelosuppression using diphtheria toxin-interleukin 3 fusion protein Journal of Clinical Oncology. 25: 7068-7068. DOI: 10.1200/Jco.2007.25.18_Suppl.7068 |
0.401 |
|
| 2007 |
Frankel AE, Smith E, George T, Liu J, Lee J, Park S, Rizzieri DA, Hogge DE. Phase I Study Demonstrates Activity and Tolerability of Diphtheria Toxin Interleukin-3 Fusion Protein in Patients with AML and MDS. Blood. 110: 894-894. DOI: 10.1182/blood.v110.11.894.894 |
0.377 |
|
| 2007 |
Narayanan S, Barnett MJ, Mourad YRA, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Smith CA, Power M, Nevill TJ. Higher CD 34 Cell Doses Reduce Non Relapse Mortality (NRM) and Do Not Increase the Incidence of Graft Versus Host Disease (GVHD) Following Unrelated Donor Blood Stem Cell Transplantation (SCT). Blood. 110: 5091-5091. DOI: 10.1182/blood.v110.11.5091.5091 |
0.31 |
|
| 2007 |
Power MM, Di Sauro G, Brooks-Wilson A, Nevill TJ, Lavoie JC, Smith CA, Shepherd JD, Toze CL, Sutherland HJ, Barnett MJ, Mourad YAA, Song KW, Forrest DM, Nantel SH, Wong SC, ... ... Hogge DE, et al. Allogeneic Stem Cell Transplant in First Complete Remission Overcomes the Poor Prognosis Associated with the FLT-3 Internal Tandem Duplication in Acute Myeloid Leukemia. Blood. 110: 3491-3491. DOI: 10.1182/Blood.V110.11.3491.3491 |
0.386 |
|
| 2007 |
Ho MM, Hogge DE, Ling V. High Expression of MDR1 and BCRP1 in Leukemic Stem Cells Correlates with Reversible Drug Resistance Ex Vivo and Predicts Failure of Remission Induction Chemotherapy in Patients with Acute Myeloid Leukemia. Blood. 110: 3385-3385. DOI: 10.1182/Blood.V110.11.3385.3385 |
0.454 |
|
| 2007 |
O’Leary HM, Savage KJ, Toze CL, Connors JM, Gascoyne RD, Mourad YA, Barnett MJ, Forrest DL, Hogge DE, Lavoie J, Nantel SH, Nevill TJ, Shepherd JD, Smith C, Sutherland HJ, et al. Allogeneic Stem Cell Transplantation as Treatment for Relapsed and High-Risk Peripheral T-Cell Lymphoma. Blood. 110: 3040-3040. DOI: 10.1182/Blood.V110.11.3040.3040 |
0.495 |
|
| 2007 |
Brune ML, Rowe JM, Szer J, Hogge DE, Catalano J, Wallhult E, Nilsson BI, Simonsson B, Spearing R, Allard S, Stadtmauer EA, Hellstrand K. Post-Consolidation Immunotherapy with Histamine Dihydrochloride and Interleukin-2 in AML: Long Term Follow-Up of Leukemia-Free Survival and Overall Survival. Blood. 110: 1846-1846. DOI: 10.1182/Blood.V110.11.1846.1846 |
0.396 |
|
| 2007 |
Narayanan S, Barnett MJ, Mourad YRA, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Smith CA, Power M, Nevill TJ. Stem Cell Transplantation (SCT) Improves Survival in Acute Biphenotypic (ABL) and Acute Undifferentiated Leukemia (AUL): A Single Centre Experience. Blood. 110: 1093-1093. DOI: 10.1182/Blood.V110.11.1093.1093 |
0.412 |
|
| 2006 |
Lin Y, Bruyère H, Horsman DE, Pantzar T, Barnett MJ, Hogge DE, Nevill TJ, Nantel SH, Sutherland HJ, Toze CL, Shepherd JD, Lavoie JC, Song KW, Smith CA, Forrest DL. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genetics and Cytogenetics. 170: 16-23. PMID 16965950 DOI: 10.1016/J.Cancergencyto.2006.04.012 |
0.362 |
|
| 2006 |
Yalcintepe L, Frankel AE, Hogge DE. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood. 108: 3530-7. PMID 16882709 DOI: 10.1182/Blood-2006-04-013813 |
0.337 |
|
| 2006 |
Song KW, Barnett MJ, Gascoyne RD, Horsman DE, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Voss NJ, Toze CL, Connors JM. Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. British Journal of Haematology. 133: 634-7. PMID 16704438 DOI: 10.1111/J.1365-2141.2006.06080.X |
0.469 |
|
| 2006 |
Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann WK, Hogge DE, Nilsson B, Or R, Romero AI, Rowe JM, Simonsson B, Spearing R, Stadtmauer EA, Szer J, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood. 108: 88-96. PMID 16556892 DOI: 10.1182/Blood-2005-10-4073 |
0.396 |
|
| 2006 |
Johny A, Song KW, Nantel SH, Lavoie JC, Toze CL, Hogge DE, Forrest DL, Sutherland HJ, Le A, Nitta JY, Barnett MJ, Smith CA, Shepherd JD, Nevill TJ. Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 12: 480-9. PMID 16545732 DOI: 10.1016/J.Bbmt.2005.12.031 |
0.516 |
|
| 2006 |
Savoie ML, Nevil TJ, Song KW, Forrest DL, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Lavoie JC. Shifting to outpatient management of acute myeloid leukemia: a prospective experience. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 17: 763-8. PMID 16497826 DOI: 10.1093/Annonc/Mdl011 |
0.441 |
|
| 2006 |
Hogge DE, Yalcintepe L, Wong SH, Gerhard B, Frankel AE. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1284-91. PMID 16489085 DOI: 10.1158/1078-0432.Ccr-05-2070 |
0.304 |
|
| 2006 |
Frankel AE, Weir MA, Hall PD, Hogge DE, Rizzieri DA. Diptheria toxin-interleukin 3 fusion protein therapy of patients with elderly or relapsed/refractory acute myeloid leukemia (AML) Journal of Clinical Oncology. 24: 6569-6569. DOI: 10.1200/Jco.2006.24.18_Suppl.6569 |
0.359 |
|
| 2006 |
Ramadan KM, Connors JM, Gascoyne RD, Song K, Barnett MJ, Nantel SH, Nevill TJ, Shepherd JD, Sutherland HJ, Lavoie J, Forrest DL, Hogge DE, Voss NJ, Brinkman R, Smith CA, et al. Long Term Results of Myeloablative Allogeneic Stem Cell Transplantation Using Related and Unrelated Donors in Patients with Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma. Blood. 108: 3139-3139. DOI: 10.1182/Blood.V108.11.3139.3139 |
0.347 |
|
| 2006 |
Irvine DA, Barnett MJ, Brinkman R, Forrest DL, Hogge DE, Lavoie J, Lei L, Nantel SH, Nevill TJ, Nitta J, Shepherd J, Song K, Toze C, Sutherland H. Induction Therapy with High-Dose Dex Alone in Newly Diagnosed Myeloma Patients Produces a 57% Partial Response and Is Predictive of Progression Free Survival. Blood. 108: 3098-3098. DOI: 10.1182/Blood.V108.11.3098.3098 |
0.427 |
|
| 2006 |
Muranyi A, Dedhar S, Hogge DE. Integrin Linked Kinase Is Expressed in Acute Myeloid Leukemia Blasts and Its Inhibition Is Cytotoxic to Leukemic Progenitors. Blood. 108: 154-154. DOI: 10.1182/Blood.V108.11.154.154 |
0.355 |
|
| 2005 |
Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD, Sutherland HJ, Toze CL, Smith CA, Lavoie JC, Song KW, Voss NJ, Gascoyne RD, Connors JM. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7994-8002. PMID 16204014 DOI: 10.1200/Jco.2005.01.9083 |
0.45 |
|
| 2005 |
Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW. Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma. British Journal of Haematology. 131: 223-30. PMID 16197454 DOI: 10.1111/J.1365-2141.2005.05755.X |
0.481 |
|
| 2005 |
Toze CL, Galal A, Barnett MJ, Shepherd JD, Conneally EA, Hogge DE, Nantel SH, Nevill TJ, Sutherland HJ, Connors JM, Voss NJ, Kiss TL, Messner HA, Lavoie JC, Forrest DL, et al. Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. Bone Marrow Transplantation. 36: 825-30. PMID 16151430 DOI: 10.1038/sj.bmt.1705130 |
0.345 |
|
| 2005 |
Song KW, Mollee PN, Hogge DE, Gupta V, Barnett MJ, Forrest DL, Lavoie JC, Nevill TJ, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Crump M, Keating A. Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission. Leukemia & Lymphoma. 46: 525-31. PMID 16019480 DOI: 10.1080/10428190400025112 |
0.479 |
|
| 2005 |
Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJ, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood. 106: 1473-8. PMID 15870180 DOI: 10.1182/Blood-2004-12-4689 |
0.476 |
|
| 2005 |
Mourad YRA, Nantel SH, Toze CL, Nevill TJ, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Shepherd JD, Sutherland HJ, Smith CA, Song KW. Long-Term Follow-Up Results of Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL)-The Vancouver Experience. Blood. 106: 4578-4578. DOI: 10.1182/blood.v106.11.4578.4578 |
0.346 |
|
| 2005 |
Hogge D, Wong S, Yalcintepe L, Frankel A. The use of mouse models of normal and malignant hematopoiesis to design strategies for selective purging of primitive acute myeloid leukemia (AML) progenitors Biology of Blood and Marrow Transplantation. 11: 60. DOI: 10.1016/J.Bbmt.2004.12.181 |
0.335 |
|
| 2004 |
Toze CL, Barnett MJ, Connors JM, Gascoyne RD, Voss NJ, Nantel SH, Nevill TJ, Shepherd JD, Sutherland HJ, Lavoie JC, Forrest DL, Song KW, Hogge DE. Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. British Journal of Haematology. 127: 311-21. PMID 15491292 DOI: 10.1111/j.1365-2141.2004.05194.x |
0.358 |
|
| 2004 |
Kuruvilla J, Forrest DL, Lavoie JC, Nantel SH, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Hogge DE, Nevill TJ. Characteristics and outcome of patients developing endocarditis following hematopoietic stem cell transplantation. Bone Marrow Transplantation. 34: 969-73. PMID 15489882 DOI: 10.1038/Sj.Bmt.1704655 |
0.42 |
|
| 2004 |
Hogge DE, Feuring-Buske M, Gerhard B, Frankel AE. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. Leukemia Research. 28: 1221-6. PMID 15380349 DOI: 10.1016/J.Leukres.2004.03.015 |
0.352 |
|
| 2004 |
Khoury H, Dalal BI, Nantel SH, Horsman DE, Lavoie JC, Shepherd JD, Hogge DE, Toze CL, Song KW, Forrest DL, Sutherland HJ, Nevill TJ. Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21). Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 17: 1211-6. PMID 15181451 DOI: 10.1038/Modpathol.3800168 |
0.368 |
|
| 2004 |
Urieto JO, Liu T, Black JH, Cohen KA, Hall PD, Willingham MC, Pennell LK, Hogge DE, Kreitman RJ, Frankel AE. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expression and Purification. 33: 123-33. PMID 14680969 DOI: 10.1016/J.Pep.2003.09.003 |
0.311 |
|
| 2004 |
Nicolini FE, Cashman JD, Hogge DE, Humphries RK, Eaves CJ. NOD/SCID mice engineered to express human IL-3, GM-CSF and Steel factor constitutively mobilize engrafted human progenitors and compromise human stem cell regeneration. Leukemia. 18: 341-7. PMID 14628073 DOI: 10.1038/Sj.Leu.2403222 |
0.335 |
|
| 2004 |
Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, Lee CY, Spinelli JJ, Sutherland HJ, Tsang P, Hogge DE. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood. 103: 333-9. PMID 12958065 DOI: 10.1182/Blood-2003-03-0940 |
0.384 |
|
| 2004 |
Song KW, Nevill TJ, Gascoyne RD, Toze CL, Barnett MB, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Smith CA, Sutherland HJ, Voss NJ, Connors JM. Hematopoietic Stem Cell Transplant (HSCT) as Primary Treatment for T-Cell Lymphobastic Lymphoma (T-LBL) : An Intention to Treat Analysis. Blood. 104: 900-900. DOI: 10.1182/Blood.V104.11.900.900 |
0.469 |
|
| 2004 |
Doocey RT, Greenwood MJ, Warkentin D, Song KW, Le A, Nitta J, Nevill TJ, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Toze CL, et al. Daclizumab Therapy Improves Outcome in Steroid Refractory Acute Graft Versus Host Disease (aGVHD). Blood. 104: 5092-5092. DOI: 10.1182/blood.v104.11.5092.5092 |
0.335 |
|
| 2004 |
Lin Y, Bruyere H, Horsman DE, Barnett MJ, Hogge DE, Nevill TJ, Nantel SH, Sutherland HJ, Toze CL, Shepherd JD, Lavoie JC, Song KW, Smith CA, Forrest DL. Philadelphia-Negative Clonal Hematopoiesis Following Imatinib Therapy in Patients with Chronic Myeloid Leukemia (CML). Blood. 104: 4696-4696. DOI: 10.1182/Blood.V104.11.4696.4696 |
0.336 |
|
| 2004 |
Doocey RT, Nantel SH, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nevill TJ, Shepherd JD, Song KW, Sutherland HJ, Toze CL, Smith CA. Risk Stratification in Acute Promyelocytic Leukemia Based on Elevated White Cell Count and Reduced Platelet Count Does Not Identify Subsequent Relapses: A Retrospective Review of 60 Patients. Blood. 104: 4522-4522. DOI: 10.1182/blood.V104.11.4522.4522 |
0.309 |
|
| 2004 |
Doocey RT, Song KW, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss N, Smith CA. Acceptable Outcomes for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) for Relapsed Aggressive Non-Hodgkin’s Lymphoma (NHL). Blood. 104: 3325-3325. DOI: 10.1182/blood.v104.11.3325.3325 |
0.37 |
|
| 2004 |
Toze CL, Hogge DE, Barnett MJ, Nevill TJ, Nantel SH, Sutherland HJ, Shepherd JD, Song KW, Forrest DL, Lavoie JC, Connors JM, Gascoyne RD, Voss NJ, Smith CA. Long-Term Results of Allogeneic Hematopoietic Stem Cell Transplantation Using Unrelated or HLA Mismatched Family Donors for Acute and Chronic Lymphoid Malignancy. Blood. 104: 2764-2764. DOI: 10.1182/Blood.V104.11.2764.2764 |
0.445 |
|
| 2004 |
Brune M, Castaigne S, Catalano J, Gehlsen K, Hofmann W, Ho A, Hogge D, Nilsson B, Or R, Rowe J, Simonsson B, Spearing R, Stadtmauer E, Szer J, Wallhult E, et al. Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial. Blood. 104: 261-261. DOI: 10.1182/Blood.V104.11.261.261 |
0.375 |
|
| 2004 |
Ho M, Hogge DE, Ling V. Expression of the Human ATP-Binding Cassette Transporter Superfamily in Acute Myeloid Leukemia. Blood. 104: 1179-1179. DOI: 10.1182/Blood.V104.11.1179.1179 |
0.388 |
|
| 2003 |
Forrest DL, Nevill TJ, Naiman SC, Le A, Brockington DA, Barnett MJ, Lavoie JC, Nantel SH, Song KW, Shepherd JD, Sutherland HJ, Toze CL, Davis JH, Hogge DE. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis. Bone Marrow Transplantation. 32: 915-23. PMID 14561993 DOI: 10.1038/sj.bmt.1704243 |
0.312 |
|
| 2003 |
Zhang Y, Dawson MI, Ning Y, Polin L, Parchment RE, Corbett T, Mohamed AN, Feng KC, Farhana L, Rishi AK, Hogge D, Leid M, Peterson VJ, Zhang XK, Mohammad R, et al. Induction of apoptosis in retinoid-refractory acute myelogenous leukemia by a novel AHPN analog. Blood. 102: 3743-52. PMID 12893763 DOI: 10.1182/Blood-2003-01-0108 |
0.393 |
|
| 2003 |
Pineault N, Buske C, Feuring-Buske M, Abramovich C, Rosten P, Hogge DE, Aplan PD, Humphries RK. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood. 101: 4529-38. PMID 12543865 DOI: 10.1182/Blood-2002-08-2484 |
0.387 |
|
| 2003 |
Black JH, McCubrey JA, Willingham MC, Ramage J, Hogge DE, Frankel AE. Diphtheria-toxin-interleukin-3 fusion protein (DT388IL3) prolongs disease-free survival of leukemic immunocompromised mice Leukemia. 17: 155-159. PMID 12529673 DOI: 10.1038/Sj.Leu.2402744 |
0.364 |
|
| 2003 |
Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood. 101: 3142-9. PMID 12468427 DOI: 10.1182/Blood-2002-10-3062 |
0.68 |
|
| 2002 |
Seftel MD, Bruyere H, Copland M, Hogge DE, Horsman DE, Nantel SH, Shepherd JD, Lavoie JC, Le A, Sutherland HJ, Toze CL, Nevill TJ. Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22). European Journal of Haematology. 69: 193-9. PMID 12431237 DOI: 10.1034/J.1600-0609.2002.02802.X |
0.454 |
|
| 2002 |
Frankel AE, Beran M, Hogge DE, Powell BL, Thorburn A, Chen YQ, Vallera DA. Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein. Experimental Hematology. 30: 1316-23. PMID 12423685 DOI: 10.1016/S0301-472X(02)00925-6 |
0.416 |
|
| 2002 |
Chalandon Y, Barnett MJ, Horsman DE, Conneally EA, Nantel SH, Nevill TJ, Nitta J, Shepherd JD, Sutherland HJ, Toze CL, Hogge DE. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 8: 435-43. PMID 12234169 DOI: 10.1053/Bbmt.2002.V8.Pm12234169 |
0.477 |
|
| 2002 |
Guan Y, Ralph S, Hogge DE. Polyclonal normal hematopoietic progenitors in patients with acute myeloid leukemia. Experimental Hematology. 30: 721-8. PMID 12135669 DOI: 10.1016/S0301-472X(02)00824-X |
0.694 |
|
| 2002 |
Buske C, Feuring-Buske M, Abramovich C, Spiekermann K, Eaves CJ, Coulombel L, Sauvageau G, Hogge DE, Humphries RK. Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cells. Blood. 100: 862-8. PMID 12130496 DOI: 10.1182/Blood-2002-01-0220 |
0.354 |
|
| 2002 |
Eisterer W, Jiang X, Bachelot T, Pawliuk R, Abramovich C, Leboulch P, Hogge D, Eaves C. Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Molecular Therapy : the Journal of the American Society of Gene Therapy. 5: 352-9. PMID 11945061 DOI: 10.1006/Mthe.2002.0573 |
0.367 |
|
| 2001 |
Frankel AE, Baer MR, Hogge DE, Stuart RK. Immunotherapy of acute myeloid leukemia Current Pharmaceutical Biotechnology. 2: 209-215. PMID 11530875 DOI: 10.2174/1389201013378699 |
0.37 |
|
| 2001 |
Feuring-Buske M, Hogge DE. Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemia. Blood. 97: 3882-9. PMID 11389030 DOI: 10.1182/Blood.V97.12.3882 |
0.325 |
|
| 2001 |
Buske C, Feuring-Buske M, Antonchuk J, Rosten P, Hogge DE, Eaves CJ, Humphries RK. Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo Blood. 97: 2286-2292. PMID 11290589 DOI: 10.1182/Blood.V97.8.2286 |
0.328 |
|
| 2000 |
Guan Y, Hogge DE. Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML). Leukemia. 14: 2135-41. PMID 11187903 DOI: 10.1038/Sj.Leu.2401975 |
0.687 |
|
| 2000 |
Feuring-Buske M, Frankel AE, Gerhard B, Hogge D. Variable cytotoxicity of diphtheria toxin 388–granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells Experimental Hematology. 28: 1390-1400. PMID 11146161 DOI: 10.1016/S0301-472X(00)00542-7 |
0.461 |
|
| 2000 |
Frankel AE, McCubrey JA, Miller MS, Delatte S, Ramage J, Kiser M, Kucera GL, Alexander RL, Beran M, Tagge EP, Kreitman RJ, Hogge DE. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia. 14: 576-85. PMID 10764142 DOI: 10.1038/Sj.Leu.2401743 |
0.447 |
|
| 2000 |
Hogge DE, Lambie K, Sutherland HJ, Benny WB, Dalal B, Currie C, Barnett MJ, Eaves AC, Eaves CJ. Quantitation of primitive and lineage-committed progenitors in mobilized peripheral blood for prediction of platelet recovery post autologous transplant Bone Marrow Transplantation. 25: 589-598. PMID 10734292 DOI: 10.1038/Sj.Bmt.1702211 |
0.427 |
|
| 1999 |
Ailles LE, Humphries RK, Thomas TE, Hogge DE. Retroviral marking of acute myelogenous leukemia progenitors that initiate long-term culture and growth in immunodeficient mice. Experimental Hematology. 27: 1609-20. PMID 10560908 DOI: 10.1016/S0301-472X(99)00099-5 |
0.408 |
|
| 1999 |
Kawagoe H, Humphries R, Blair A, Sutherland H, Hogge D. Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Leukemia. 13: 687-698. PMID 10374871 DOI: 10.1038/Sj.Leu.2401410 |
0.378 |
|
| 1999 |
Ailles LE, Gerhard B, Kawagoe H, Hogge DE. Growth Characteristics of Acute Myelogenous Leukemia Progenitors That Initiate Malignant Hematopoiesis in Nonobese Diabetic/Severe Combined Immunodeficient Mice Blood. 94: 1761-1772. DOI: 10.1182/Blood.V94.5.1761.417K23_1761_1772 |
0.459 |
|
| 1998 |
Micallef IN, Chhanabhai M, Gascoyne RD, Shepherd JD, Fung HC, Nantel SH, Toze CL, Klingemann HG, Sutherland HJ, Hogge DE, Nevill TJ, Le A, Barnett MJ. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplantation. 22: 981-7. PMID 9849695 DOI: 10.1038/Sj.Bmt.1701468 |
0.462 |
|
| 1998 |
Hogge DE, Willman CL, Kreitman RJ, Berger M, Hall PD, Kopecky KJ, McLain C, Tagge EP, Eaves CJ, Frankel AE. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. Blood. 92: 589-95. PMID 9657759 |
0.318 |
|
| 1998 |
Nevill TJ, Fung HC, Shepherd JD, Horsman DE, Nantel SH, Klingemann H, Forrest DL, Toze CL, Sutherland HJ, Hogge DE, Naiman SC, Le A, Brockington DA, Barnett MJ. Cytogenetic Abnormalities in Primary Myelodysplastic Syndrome Are Highly Predictive of Outcome After Allogeneic Bone Marrow Transplantation Blood. 92: 1910-1917. DOI: 10.1182/BLOOD.V92.6.1910.418K30_1910_1917 |
0.313 |
|
| 1998 |
Hogge DE, Willman CL, Kreitman RJ, Berger M, Hall PD, Kopecky KJ, McLain C, Tagge EP, Eaves CJ, Frankel AE. Malignant Progenitors From Patients With Acute Myelogenous Leukemia Are Sensitive to a Diphtheria Toxin-Granulocyte-Macrophage Colony-Stimulating Factor Fusion Protein Blood. 92: 589-595. DOI: 10.1182/Blood.V92.2.589.414K20_589_595 |
0.426 |
|
| 1998 |
Frankel AE, Lilly M, Kreitman R, Hogge D, Beran M, Freedman MH, Emanuel PD, McLain C, Hall P, Tagge E, Berger M, Eaves C. Diphtheria Toxin Fused to Granulocyte-Macrophage Colony-Stimulating Factor Is Toxic to Blasts From Patients With Juvenile Myelomonocytic Leukemia and Chronic Myelomonocytic Leukemia Blood. 92: 4279-4286. DOI: 10.1182/Blood.V92.11.4279.423K26_4279_4286 |
0.441 |
|
| 1997 |
Ponchio L, Eaves C, Hogge D, Perotti C, Torretta L, Cerani P, Salvaneschi L, Ascari E, Cazzola M. Both cycling and noncycling primitive progenitors continue to be mobilized into the circulation during the leukapheresis of patients pretreated with chemotherapy and G-CSF. British Journal of Haematology. 99: 394-402. PMID 9375761 DOI: 10.1046/J.1365-2141.1997.3963210.X |
0.357 |
|
| 1997 |
Cashman J, Bockhold K, Hogge DE, Eaves AC, Eaves CJ. Sustained proliferation, multi-lineage differentiation and maintenance of primitive human haemopoietic cells in NOD/SCID mice transplanted with human cord blood. British Journal of Haematology. 98: 1026-36. PMID 9326207 DOI: 10.1046/J.1365-2141.1997.3233140.X |
0.369 |
|
| 1997 |
Hogge D, Fanning S, Bockhold K, Petzer A, Lambie K, Lansdorp P, Eaves A, Eaves C. Quantitation and characterization of human megakaryocyte colony-forming cells using a standardized serum-free agarose assay. British Journal of Haematology. 96: 790-800. PMID 9074423 DOI: 10.1046/J.1365-2141.1997.D01-2092.X |
0.334 |
|
| 1997 |
Ailles LE, Gerhard B, Hogge DE. Detection and Characterization of Primitive Malignant and Normal Progenitors in Patients With Acute Myelogenous Leukemia Using Long-Term Coculture With Supportive Feeder Layers and Cytokines Blood. 90: 2555-2564. DOI: 10.1182/Blood.V90.7.2555.2555_2555_2564 |
0.427 |
|
| 1996 |
Petzer AL, Hogge DE, Landsdorp PM, Reid DS, Eaves CJ. Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined medium. Proceedings of the National Academy of Sciences of the United States of America. 93: 1470-4. PMID 8643656 DOI: 10.1073/Pnas.93.4.1470 |
0.34 |
|
| 1995 |
Reece D, Barnett M, Shepherd J, Hogge D, Klasa R, Nantel S, Sutherland H, Klingemann H, Fairey R, Voss N. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy Blood. 86: 451-456. DOI: 10.1182/blood.V86.2.451.bloodjournal862451 |
0.408 |
|
| 1994 |
Hogge DE, Sutherland HJ, Cashman JD, Lansdorp PM, Humphries RK, Eaves CJ. Cytokines acting early in human haematopoiesis. Bailliere's Clinical Haematology. 7: 49-63. PMID 8038499 DOI: 10.1016/S0950-3536(05)80006-X |
0.333 |
|
| 1994 |
Sauvageau G, Lansdorp PM, Eaves CJ, Hogge DE, Dragowska WH, Reid DS, Largman C, Lawrence HJ, Humphries RK. Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells Proceedings of the National Academy of Sciences of the United States of America. 91: 12223-12227. PMID 7527557 DOI: 10.1073/Pnas.91.25.12223 |
0.316 |
|
| 1994 |
Thacker JD, Dedhar S, Hogge DE. The effect of GM-CSF and G-CSF on the growth of human osteosarcoma cells in vitro and in vivo. International Journal of Cancer. 56: 236-43. PMID 7508889 DOI: 10.1002/Ijc.2910560216 |
0.315 |
|
| 1994 |
Barnett M, Eaves C, Phillips G, Gascoyne R, Hogge D, Horsman D, Humphries R, Klingemann H, Lansdorp P, Nantel S. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study [see comments] Blood. 84: 724-732. DOI: 10.1182/blood.V84.3.724.bloodjournal843724 |
0.303 |
|
| 1994 |
Sutherland H, Eaves C, Lansdorp P, Phillips G, Hogge D. Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in autotransplants Blood. 83: 3808-3814. DOI: 10.1182/blood.v83.12.3808.bloodjournal83123808 |
0.341 |
|
| 1994 |
Sutherland H, Eaves C, Lansdorp P, Phillips G, Hogge D. Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in autotransplants Blood. 83: 3808-3814. DOI: 10.1182/Blood.V83.12.3808.3808 |
0.341 |
|
| 1993 |
Barnett MJ, Eaves CJ, Phillips GL, Hogge DE, Klingemann HG, Lansdorp PM, Nantel SH, Reece DE, Shepherd JD, Sutherland HJ. Autografting in chronic myeloid leukemia with cultured marrow: update of the Vancouver Study. Stem Cells (Dayton, Ohio). 11: 64-6. PMID 7905324 DOI: 10.1002/Stem.5530110916 |
0.405 |
|
| 1991 |
Eaves CJ, Cashman JD, Sutherland HJ, Otsuka T, Humphries RK, Hogge DE, Lansdorp PL, Eaves AC. Molecular analysis of primitive hematopoietic cell proliferation control mechanisms. Annals of the New York Academy of Sciences. 628: 298-306. PMID 1712556 DOI: 10.1111/J.1749-6632.1991.Tb17260.X |
0.365 |
|
| 1991 |
Hogge D, Cashman J, Humphries R, Eaves C. Differential and synergistic effects of human granulocyte-macrophage colony-stimulating factor and human granulocyte colony-stimulating factor on hematopoiesis in human long-term marrow cultures Blood. 77: 493-499. DOI: 10.1182/Blood.V77.3.493.Bloodjournal773493 |
0.312 |
|
| 1987 |
Hogge DE, Shannon KM, Kalousek DK, Schonberg S, Schaffner V, Zoger S, Eaves CJ, Eaves AC. Juvenile monosomy 7 syndrome: evidence that the disease originates in a pluripotent hemopoietic stem cell. Leukemia Research. 11: 705-9. PMID 3626612 DOI: 10.1016/0145-2126(87)90006-3 |
0.467 |
|
| 1987 |
Hogge DE, Coulombel L, Kalousek DK, Eaves CJ, Eaves AC. Nonclonal hemopoietic progenitors in a G6PD heterozygote with chronic myelogenous leukemia revealed after long-term marrow culture. American Journal of Hematology. 24: 389-94. PMID 3471084 DOI: 10.1002/Ajh.2830240408 |
0.366 |
|
| 1984 |
Hogge DE, Misawa S, Parsa NZ, Pollak A, Testa JR. Abnormalities of chromosome 16 in association with acute myelomonocytic leukemia and dysplastic bone marrow eosinophils. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2: 550-7. PMID 6587018 DOI: 10.1200/Jco.1984.2.6.550 |
0.392 |
|
| 1983 |
Schiffer C, Dutcher J, Aisner J, Hogge D, Wiernik P, Reilly J. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia Blood. 62: 815-820. DOI: 10.1182/Blood.V62.4.815.Bloodjournal624815 |
0.374 |
|
| Show low-probability matches. |